Short answer
Eton Pharmaceuticals, Inc. (ETON) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $38M (up 98.6% year over year) with net income of $12M.
Q2 2026 key financials · XBRL
- Revenue
- $38M
- +98.6% YoY · +54.9% QoQ
- Net income
- $12M
- +547.9% YoY · +645.0% QoQ
- Operating margin
- 34.0%
- Gross margin
- 67.6%
- EPS (diluted)
- $0.36
- +500.0% YoY · +620.0% QoQ
Source: XBRL data from the Eton Pharmaceuticals, Inc. (ETON) Q2 2026 10-Q on SEC EDGAR. USD.
Eton Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $37.589M, up $18.661M YoY from $18.928M
- Gross margin 67.6% vs 63.0% YoY, based on gross profit of $25.413M vs $11.924M
- Best performers INCRELEX®, GALZIN®, Carglumic Acid and HEMANGEOL® additions; no product-level figures disclosed
- Cash $26.8M at June 30; operating cash flow $14.660M vs $10.049M YoY
- $15.070M investing outflow, including $14.000M HEMANGEOL® rights acquisition and $1.000M licensing payment
Risk Factors
- No Risk Factors section provided; filing excerpt contains Items 2–6 and signatures only
- Cashless warrant exercises issued 296,215 shares at weighted average exercise price of $31.83
- Warrant exercises generated no cash proceeds and surrendered 62,901 warrants
- Sixth Amendment to Credit Agreement with SWK Funding LLC dated April 6, 2026
- Asset Purchase Agreement with Knight Therapeutics Europe S.A. dated May 18, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Eton Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.